Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Suhaj Abdulsalim, Munawar Peringadi Vayalil & Sonal Sekhar Miraj. (2016) New fixed dose chemical combinations: the way forward for better diabetes type II management?. Expert Opinion on Pharmacotherapy 17:16, pages 2207-2214.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
André J Scheen. (2012) Saxagliptin plus metformin combination therapy. Expert Review of Endocrinology & Metabolism 7:2, pages 151-164.
Read now
Read now
André J Scheen. (2012)
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment. Expert Opinion on Drug Metabolism & Toxicology 8:3, pages 383-394.
Read now
Read now
André J Scheen. (2012) Metformin + saxagliptin for type 2 diabetes. Expert Opinion on Pharmacotherapy 13:1, pages 139-146.
Read now
Read now
André J Scheen. (2011) Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opinion on Drug Metabolism & Toxicology 7:12, pages 1561-1576.
Read now
Read now
Articles from other publishers (32)
Yi Hu, Periyannan Velu, Pejman Rohani & Mohammad Hassan Sohouli. (2023)
Changes in lipid profile and glucose metabolism following administration of bupropion alone or in combination with naltrexone: A systematic review and
meta‐regression
analysis
. European Journal of Clinical Investigation.
Crossref
Crossref
Maryam S. Hafiz, Matthew D. Campbell, Lauren L. O’Mahoney, Melvin Holmes, Caroline Orfila & Christine Boesch. (2021) Pulse consumption improves indices of glycemic control in adults with and without type 2 diabetes: a systematic review and meta-analysis of acute and long-term randomized controlled trials. European Journal of Nutrition 61:2, pages 809-824.
Crossref
Crossref
Kerem Tok, Hichem Moulahoum, Ebru Kocadag Kocazorbaz & Figen Zihnioglu. 2022. Bioactive Natural Products. Bioactive Natural Products
41
74
.
Maryna van de Venter, Jenske Didloff, Shanika Reddy, Bresler Swanepoel, Sharlene Govender, Ntokozo Shirley Dambuza, Saralene Williams, Trevor Craig Koekemoer & Luanne Venables. (2020) Wild-Type Zebrafish (Danio rerio) Larvae as a Vertebrate Model for Diabetes and Comorbidities: A Review. Animals 11:1, pages 54.
Crossref
Crossref
Yuji Kawaguchi, Jun Sawa & Yasuro Kumeda. (2020) Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring. Diabetes Therapy 11:12, pages 2945-2958.
Crossref
Crossref
Sanjay Kalra, Sarita Bajaj, AG Unnikrishnan, ManashP Baruah, Rakesh Sahay, V Hardik & Amit Kumar. (2019) Therapeutic experience of saxagliptin as first add-on after metformin in Indian type 2 diabetes patients: A non-interventional, prospective, observational study (ONTARGET-INDIA). Indian Journal of Endocrinology and Metabolism 23:3, pages 312.
Crossref
Crossref
M. C. Sharma, S. Jain & R. Sharma. (2017) Trifluorophenyl-based inhibitors of dipeptidyl peptidase-IV as antidiabetic agents: 3D-QSAR COMFA, CoMSIA methodologies. Network Modeling Analysis in Health Informatics and Bioinformatics 7:1.
Crossref
Crossref
Debbie A. Hinnen. (2015) Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. Clinical Diabetes 33:4, pages 175-180.
Crossref
Crossref
Mariam Philip Riya, Kalathookunnel Antony Antu, Savita Pal, Karuvakandy Chandrasekharan Chandrakanth, Karunakaran Sasikala Anilkumar, Akhilesh Kumar Tamrakar, Arvind Kumar Srivastava & Kozhiparambil Gopalan Raghu. (2015)
Antidiabetic property of
Aerva lanata
(L.) Juss. ex Schult. is mediated by inhibition of alpha glucosidase, protein glycation and stimulation of adipogenesis
软毛白花苋
(L.)的降糖特性是通过对α葡萄糖甙酶与蛋白质糖基化的抑制以及脂肪生成的刺激达成的
. Journal of Diabetes 7:4, pages 548-561.
Crossref
Crossref
Yan Ran, Heying Pei, Caifeng Xie, Liang Ma, Yuzhe Wu, Kai Lei, Mingfeng Shao, Minghai Tang, Mingli Xiang, Aihua Peng, Yuquan Wei & Lijuan Chen. (2015) Scaffold-based design of xanthine as highly potent inhibitors of DPP-IV for improving glucose homeostasis in DIO mice. Molecular Diversity 19:2, pages 333-346.
Crossref
Crossref
Lawrence Blonde, Zinnia T. San Juan & Peggy Bolton. (2014) Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus. Endocrine Practice 20:12, pages 1322-1332.
Crossref
Crossref
Sinan Wang, Mingbo Su, Jiang Wang, Zeng Li, Lei Zhang, Xun Ji, Jingya Li, Jia Li & Hong Liu. (2014) ( R )-3-Amino-1-((3a S ,7a S )-octahydro-1 H -indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: Design, synthesis, biological evaluation, and molecular modeling. Bioorganic & Medicinal Chemistry 22:23, pages 6684-6693.
Crossref
Crossref
Atsunori Kashiwagi, Kenichi Kazuta, Satoshi Yoshida & Itsuro Nagase. (2013) Randomized, placebo‐controlled, double‐blind glycemic control trial of novel sodium‐dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 5:4, pages 382-391.
Crossref
Crossref
Katherine A. Lyseng-Williamson & Lily P. H. Yang. (2014) Saxagliptin: a guide to its use in type 2 diabetes mellitus. Drugs & Therapy Perspectives 30:3, pages 92-99.
Crossref
Crossref
Priscilla Hollander, Alok K. Gupta, Raymond Plodkowski, Frank Greenway, Harold Bays, Colleen Burns, Preston Klassen & Ken Fujioka. (2013) Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes. Diabetes Care 36:12, pages 4022-4029.
Crossref
Crossref
Hui Xie, Lili Zeng, Shaogao Zeng, Xin Lu, Xin Zhao, Guicheng Zhang, Zhengchao Tu, Hongjiang Xu, Ling Yang, Xiquan Zhang, Shanchun Wang & Wenhui Hu. (2013) Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization. European Journal of Medicinal Chemistry 68, pages 312-320.
Crossref
Crossref
Shaogao Zeng, Hui Xie, Li-li Zeng, Xin Lu, Xin Zhao, Gui-cheng Zhang, Zheng-chao Tu, Hong-jiang Xu, Ling Yang, Xi-quan Zhang & Wenhui Hu. (2013) Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization. Bioorganic & Medicinal Chemistry 21:7, pages 1749-1755.
Crossref
Crossref
Erin D Roe, Natalie C Pon, Priscilla Hollander & Philip Raskin. (2013) The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes. Diabetes Management 3:2, pages 145-160.
Crossref
Crossref
Andrew J. Lewin, Lisa Arvay, Dacheng Liu, Sanjay Patel, Maximilian von Eynatten & Hans-Juergen Woerle. (2012) Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Therapeutics 34:9, pages 1909-1919.e15.
Crossref
Crossref
Hui Xie, Lili Zeng, Shaogao Zeng, Xin Lu, Guicheng Zhang, Xin Zhao, Na Cheng, Zhengchao Tu, Zhiyuan Li, Hongjiang Xu, Ling Yang, Xiquan Zhang, Min Huang, Junling Zhao & Wenhui Hu. (2012) Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. European Journal of Medicinal Chemistry 52, pages 205-212.
Crossref
Crossref
Christopher Habib, Matthew Gowan, Stefan Podgrabinski, Tom Grodski, Brenda Leung, Maria Shapoval, Dugald Seely & Kieran Cooley. (2012) Treating Type 2 Diabetes: A Cross-sectional Audit of Naturopathic Standards of Care Using the Naturopathic Patient Database. Journal of Evidence-Based Complementary & Alternative Medicine 17:2, pages 108-116.
Crossref
Crossref
Wilma Erhardt, Klas Bergenheim, Isabelle Duprat-Lomon & Phil McEwan. (2012) Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. Clinical Drug Investigation 32:3, pages 189-202.
Crossref
Crossref
Apostolis Mangou, Maria G. Grammatikopoulou, Daphne Mirkopoulou, Nikolaos Sailer, Charalambos Kotzamanidis & Maria Tsigga. (2012) Associations between diet quality, health status and diabetic complications in patients with type 2 diabetes and comorbid obesity. Endocrinología y Nutrición 59:2, pages 109-116.
Crossref
Crossref
Apostolis Mangou, Maria G. Grammatikopoulou, Daphne Mirkopoulou, Nikolaos Sailer, Charalambos Kotzamanidis & Maria Tsigga. (2012) Associations between diet quality, health status and diabetic complications in patients with type 2 diabetes and comorbid obesity. Endocrinología y Nutrición (English Edition) 59:2, pages 109-116.
Crossref
Crossref
Yi-Ming Mu, Anoop Misra, John M.F. Adam, Siew Pheng Chan, Francis C.C. Chow, Elaine Cheeay Cunanan, Chaicharn Deerochanawong, Hak Chul Jang, Nguyen Thy Khue, Wayne H.-H. Sheu & Kevin E.K. Tan. (2012) Managing diabetes in Asia: Overcoming obstacles and the role of DPP-IV inhibitors. Diabetes Research and Clinical Practice 95:2, pages 179-188.
Crossref
Crossref
Lily P.H. Yang. (2012) Saxagliptin. Drugs 72:2, pages 229-248.
Crossref
Crossref
Wladyslaw GrzeszczakLeszek CzupryniakKatarzyna KolasaCezary SciborskiIsabelle Duprat LomonPhil McEwan. (2012) The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland. Diabetes Technology & Therapeutics 14:1, pages 65-73.
Crossref
Crossref
Lawrence Blonde & Zinnia T. San Juan. (2012) Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus. Advances in Therapy 29:1, pages 1-13.
Crossref
Crossref
Takeshi Kadokura, Masako Saito, Atsushi Utsuno, Kenichi Kazuta, Satoshi Yoshida, Shigenori Kawasaki, Itsuro Nagase & Shigeru Kageyama. (2011) Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetology International 2:4, pages 172-182.
Crossref
Crossref
J.-F. Gautier & J.-P. Sauvanet. (2011) Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes. Annales d'Endocrinologie 72:4, pages 287-295.
Crossref
Crossref
Monika Lechleitner & Friedrich Hoppichler. (2011) Insulin therapyInsulintherapie. Wiener Medizinische Wochenschrift 161:11-12, pages 300-304.
Crossref
Crossref
Chidambarann SudhakaranUtkal KishoreRanjit Mohan AnjanaRanjit UnnikrishnanViswanathan Mohan. (2011) Effectiveness of Sitagliptin in Asian Indian Patients with Type 2 Diabetes—An Indian Tertiary Diabetes Care Center Experience. Diabetes Technology & Therapeutics 13:1, pages 27-32.
Crossref
Crossref